Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E.sup.+ T cell by an HLA-E-restricted CD8.sup.+ T cell comprising contacting the HLA-E.sup.+ T cell and CD8.sup.+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD3.sup.+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E.sup.+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E.sup.+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8.sup.+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E.sup.+ T cell, and assays for identifying such agents, are provided.

The present disclosure relates to a combination therapy comprising a therapeutic vaccine and a recombinant vaccinia virus for treating HPV-associated diseases. The present disclosure further relates to a method of administration of a combination therapy comprising a therapeutic vaccine and a recombinant vaccinia virus for treating HPV associated diseases.

This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other antigen-presenting cells in combination with anti-chemorepellant agents. This disclosure is further directed to methods of preparing T cells and methods of treating cancer, by activated T cells optionally in combination with anti-chemorepellant agents. The antigen presenting cells of the disclosure are activated by incubation with cancer cells and fusion proteins. The T cells of the disclosures are activated by incubation with activated antigen-presenting cells that were activated by incubation with cancer cells and a fusion protein. In particular, the fusion protein comprises an antigen-binding domain, e.g., an antibody or antibody fragment, and a stress protein domain.

The present disclosure is directed to co-administration of high dose Vitamin D.sub.3, heat shock proteins, glutathione, and kits provided for co-administration of these compositions, for the treatment of patients with chronic inflammation and chronic diseases.

The present disclosure is directed to co-administration of high dose Vitamin D.sub.3, heat shock proteins, glutathione, and kits provided for co-administration of these compositions, for the treatment of patients with chronic inflammation and chronic diseases.

The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.

The present invention discloses a recombinant protein capable of resisting multiple sclerosis and a preparation method and application thereof, and belongs to the technical field of biopharmacy. The recombinant protein of the present invention comprises Mycobacterium tuberculosis heat shock protein 65 and 6-segment tandem repeat myelin oligodendroglia glycoprotein antigen epitope polypeptides with multiple sclerosis autoimmune antigen characteristics at the 33rd-55th sites. The recombinant protein capable of resisting multiple sclerosis is used for preparing multiple sclerosis vaccines and/or preparing multiple sclerosis drugs. The present invention can play a role in preventing multiple sclerosis and can avoid side effects caused by most of disease modifying therapy (DMT) drugs.

The present invention relates to methods for preparing and using multichaperone-antigen complexes. The present invention uses HOP affinity molecules in affinity methods to isolate multichaperone (multi-HSP)-antigen complexes. Such complexes have use in therapy.

The present invention relates to methods of rescue and/or propagation of paramyxovirus species, particularly wherein both rescue and propagation are carried out in the same cell type; i.e., without the use of helper cells for viral rescue. The paramyxoviruses produced by the disclosed methods may encompass wild-type viruses, chimeric viruses, recombinant viruses or engineered viral products such as virus like particles (VLP). Viruses and/or viral products produced in the method according to the current invention are suitable for medical or veterinary use in such applications as treating or preventing infectious diseases, particularly avian paramyxovirus and human respiratory virus infections, and cancer treatment.

Aspects of the disclosure relate to methods of treating a subject who has had a Glioblastoma Multiforme (GBM) tumor surgically removed.